This study looks at how safe and tolerable a medicine called Pegcetacoplan (also known as Syfovre) is for people with a specific eye condition called Geographic Atrophy (GA) that comes from Age-Related Macular Degeneration (AMD). GA is when parts of the eye's macula, which helps us see clearly, get damaged. Pegcetacoplan is already used in regular medical practice, but this study wants to see how it works in the real world!

To join this study, you need to be at least 60 years old and have better than 20/200 vision on a Snellen chart. Your eye doctor will check if your GA is from AMD and if your condition meets the study's rules. You cannot join if your GA is due to other eye diseases or if you have had certain eye treatments before. The study does not involve any new or experimental treatments.

• The study is observational, meaning they will observe you without changing your regular treatment.
• You need to have a clear eye test, and give consent to join.
• No special treatments will be given; they are just watching how Syfovre works.